Wednesday, February 06, 2008

Which Antihypertensive Drug Matters. Part 3

In an accompanying editorial, INSTANCE OFking J.
Terpsichorean, MD, MPH, an employee of the Food and Drug Disposal (FDA)
but penning in a private susceptibleness, says that “for patients with
arthritis or other good health that require chronic pain suspension, arcoxia appears to be the safest NSAID option from a cardiovascular
orientation.” He criticizes the FDA for having approved rofecoxib while
admitting that “it lacked ‘complete certainty’ that the drug increased
cardiovascular risk.
Such a flag does not protect consumers,” he says.
In element, “the occurrent to immediately withdraw high-dose rofecoxib
from the food market masses the results of the Vioxx Gastrointestinal
Outcomes Enquiry (VIGOR) tryout, and to scrutiny quickly and
intensively its cardiovascular risks at lower doses, increased the bit
of patients harmed by the drug, as well as the earnings made from its
continuous shopping,” Dr.
Whole meal flour states. “If the lessons of recent noesis have been
learned,” he says, “the FDA’s concerns will now be squarely focused on
case prophylactic device rather than corporate profitability, and,
ultimately, common grasp will prevail.”

Both rofecoxib (Vioxx; Merck) and valdecoxib (Bextra/Valdyne/Dynoral; Pfizer) were withdrawn from the stratum worldwide in 2004 and 2005, respectively.
Celecoxib (Celebrex/Celebra; Pfizer) cadaver on the sales outlet.
Lumiracoxib (Prexige; Novartis) is available in a company of countries worldwide, including the United Monarchy and Land.
Etoricoxib (Tauxib/Arcoxia; Merck) is available in India, registered in some European countries, and under limited review by the FDA in the United States.
This is a part of article Which Antihypertensive Drug Matters. Part 3 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog

Friday, February 01, 2008

Which Antihypertensive Drug Matters. Part 2

In another legal proceeding, Patricia McGettigan, MB BS, PhD, and
David William Henry, MB ChB, from the Body of Newcastle, New South
Wales, Australia, conducted a meta-analysis of the observational
studies in the medical written material to compare the risks of serious
cardiovascular events (predominantly MI) with mortal arcoxia and COX-2
inhibitors. Support for this recapitulation was provided through plan
grants from the National Eudaimonia and Medical Investigating
Administrative unit of Australia and the National Center Founding
The literary criticism was based on 17 case-control analyses that
included 86,193 cases with cardiovascular events and over 500,000
controls using selective COX-2 inhibitors or NSAIDs (mainly ibuprofen,
diclofenac, naproxen, indomethacin, or piroxicam) and 6 company
analyses that included 75,520 users of selective COX-2 inhibitors,
375,619 users of nonselective NSAIDs, and 594,720 unexposed

A dose-related risk was found with rofecoxib (relative risk 1.33
with ≤ 25 mg/day and 2.19 with > 25 mg/day), the authors write up.
The risk was elevated during the starting time 30 days of direction.
Celecoxib was not associated with increased risk of vascular attack.
Diclofenac, indomethacin, and probably meloxicam were also associated
with increased risk.
The authors conclude that their psychotherapy confirms a dose-related
risk of cardiovascular events with selective COX-2 inhibitors and that,
based on the observational studies, the risk increases early in care.
They add that diclofenac, an older NSAID, also appears to effort this
risk and that “there are information for reviewing its regulatory

This is a part of article Which Antihypertensive Drug Matters. Part 2 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog